Sean Moloughney06.17.08
CP Kelco U.S., Atlanta, GA, and Fluxome Sciences A/S, Copenhagen, Denmark, have joined forces to develop resveratrol, an antioxidant believed to offer anti-aging and cardiovascular benefits.
Research into the positive effects resveratrol can have on the body has led many companies in the nutraceuticals industry to focus on the powerful antioxidant, most commonly found in grapes and red wine.
The joint agreement between CP Kelco—part of J.M. Huber Corporation, Edison, NJ—and Fluxome Sciences will focus on development of a novel fermentation process in an effort to launch and supply the market with a natural, high purity resveratrol ingredient initially positioned for nutritional supplements.
With CP Kelco’s development capabilities and Fluxome Sciences’ proprietary metabolic engineering technology platform, additional applications in foods, beverages and cosmetics are expected to follow in the future.
The companies will scale up a novel baker’s yeast strain to produce the active form of resveratrol commercially.
According to CP Kelco, the collaboration is part of the company’s long-term plan to leverage its fermentation development capabilities and global positioning to create new growth opportunities. Coupled with Fluxome Science’s technology platforms, the two are in good position to meet growing market demand for resveratrol.
Research into the positive effects resveratrol can have on the body has led many companies in the nutraceuticals industry to focus on the powerful antioxidant, most commonly found in grapes and red wine.
The joint agreement between CP Kelco—part of J.M. Huber Corporation, Edison, NJ—and Fluxome Sciences will focus on development of a novel fermentation process in an effort to launch and supply the market with a natural, high purity resveratrol ingredient initially positioned for nutritional supplements.
With CP Kelco’s development capabilities and Fluxome Sciences’ proprietary metabolic engineering technology platform, additional applications in foods, beverages and cosmetics are expected to follow in the future.
The companies will scale up a novel baker’s yeast strain to produce the active form of resveratrol commercially.
According to CP Kelco, the collaboration is part of the company’s long-term plan to leverage its fermentation development capabilities and global positioning to create new growth opportunities. Coupled with Fluxome Science’s technology platforms, the two are in good position to meet growing market demand for resveratrol.